Resmetirom: Difference between revisions

Resmetirom
	[[File:\|frameless\|220px\|alt=\|]]
INN
Drug class
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Newer edit →

Revision as of 21:30, 1 January 2025

Resmetirom is a novel, orally administered, liver-directed, selective thyroid hormone receptor-β (THR-β) agonist. It is primarily being investigated for the treatment of non-alcoholic steatohepatitis (NASH) and dyslipidemia.

Mechanism of Action

Resmetirom functions by selectively activating the thyroid hormone receptor-β (THR-β) in the liver. This receptor is involved in the regulation of lipid metabolism, cholesterol homeostasis, and energy expenditure. By targeting THR-β, resmetirom aims to reduce liver fat content, improve liver function, and decrease levels of circulating lipids such as low-density lipoprotein (LDL) cholesterol and triglycerides.

Pharmacokinetics

Resmetirom is administered orally and is designed to have a high degree of liver selectivity, minimizing systemic exposure and potential off-target effects. The drug undergoes hepatic metabolism, and its elimination half-life allows for once-daily dosing. The specific metabolic pathways and excretion routes are subjects of ongoing research.

Clinical Development

Resmetirom is currently in advanced stages of clinical trials for the treatment of NASH, a progressive liver disease characterized by steatosis, inflammation, and fibrosis. NASH can lead to cirrhosis and hepatocellular carcinoma. Resmetirom has shown promise in reducing liver fat and improving liver histology in clinical studies.

Non-Alcoholic Steatohepatitis (NASH)

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) and is associated with metabolic syndrome, obesity, and type 2 diabetes mellitus. Current treatment options are limited, and resmetirom represents a potential therapeutic advancement by addressing the underlying metabolic dysfunctions.

Dyslipidemia

Dyslipidemia, characterized by abnormal lipid levels in the blood, is a major risk factor for cardiovascular disease. Resmetirom's ability to lower LDL cholesterol and triglycerides makes it a candidate for managing dyslipidemia, particularly in patients with concurrent NASH.

Safety and Tolerability

In clinical trials, resmetirom has been generally well-tolerated. Common adverse effects include mild gastrointestinal symptoms, such as nausea and diarrhea. The liver-selective action of resmetirom is intended to reduce the risk of systemic side effects typically associated with thyroid hormone therapies.

Future Directions

Ongoing research is focused on further elucidating the long-term efficacy and safety of resmetirom in larger and more diverse patient populations. Additionally, studies are exploring its potential benefits in other metabolic disorders beyond NASH and dyslipidemia.

Conclusion

Resmetirom represents a promising therapeutic agent in the management of NASH and dyslipidemia, with its liver-targeted mechanism offering a novel approach to these challenging conditions. Continued research and clinical trials will determine its place in future treatment paradigms.

@@ Line 1: / Line 1: @@
-[[File:Resmetirom.svg|thumb|Resmetirom]] '''Resmetirom''' is a pharmaceutical compound that has garnered attention within the medical and scientific communities for its potential in treating various conditions, most notably non-alcoholic steatohepatitis (NASH). This article aims to provide a comprehensive overview of Resmetirom, including its mechanism of action, clinical trials, and potential implications for patient care.
+{{DISPLAYTITLE:Resmetirom}}
+{{Infobox drug
+| name = Resmetirom
+| image = <!-- Image of the chemical structure -->
+| width = 250
+| alt =
+| caption =
+| pronounce =
+| tradename =
+| Drugs.com =
+| MedlinePlus =
+| licence_EU =
+| DailyMedID =
+| pregnancy_AU =
+| pregnancy_US =
+| pregnancy_category =
+| routes_of_administration = Oral
+| ATC_prefix =
+| ATC_suffix =
+| legal_AU =
+| legal_BR =
+| legal_CA =
+| legal_DE =
+| legal_NZ =
+| legal_UK =
+| legal_US =
+| legal_status =
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+| CAS_number =
+| PubChem =
+| DrugBank =
+| ChemSpiderID =
+| UNII =
+| KEGG =
+| ChEBI =
+| ChEMBL =
+| synonyms =
+}}
+'''Resmetirom''' is a novel, orally administered, liver-directed, selective thyroid hormone receptor-β (THR-β) agonist. It is primarily being investigated for the treatment of [[non-alcoholic steatohepatitis]] (NASH) and [[dyslipidemia]].
 ==Mechanism of Action==
-Resmetirom functions as a selective agonist of the thyroid hormone receptor beta (THR-β). By targeting this receptor, Resmetirom aims to mimic the beneficial effects of thyroid hormones on metabolism without eliciting the adverse effects associated with thyroid hormone therapy. The activation of THR-β is believed to enhance the liver's ability to metabolize lipids and reduce liver fat, inflammation, and fibrosis, which are hallmark features of NASH.
+Resmetirom functions by selectively activating the thyroid hormone receptor-β (THR-β) in the liver. This receptor is involved in the regulation of [[lipid metabolism]], [[cholesterol]] homeostasis, and [[energy expenditure]]. By targeting THR-β, resmetirom aims to reduce liver fat content, improve liver function, and decrease levels of circulating lipids such as [[low-density lipoprotein]] (LDL) cholesterol and [[triglycerides]].
+==Pharmacokinetics==
+Resmetirom is administered orally and is designed to have a high degree of liver selectivity, minimizing systemic exposure and potential off-target effects. The drug undergoes hepatic metabolism, and its elimination half-life allows for once-daily dosing. The specific metabolic pathways and excretion routes are subjects of ongoing research.
+==Clinical Development==
+Resmetirom is currently in advanced stages of clinical trials for the treatment of NASH, a progressive liver disease characterized by [[steatosis]], [[inflammation]], and [[fibrosis]]. NASH can lead to [[cirrhosis]] and [[hepatocellular carcinoma]]. Resmetirom has shown promise in reducing liver fat and improving liver histology in clinical studies.
+===Non-Alcoholic Steatohepatitis (NASH)===
+NASH is a severe form of [[non-alcoholic fatty liver disease]] (NAFLD) and is associated with [[metabolic syndrome]], [[obesity]], and [[type 2 diabetes mellitus]]. Current treatment options are limited, and resmetirom represents a potential therapeutic advancement by addressing the underlying metabolic dysfunctions.
+===Dyslipidemia===
+Dyslipidemia, characterized by abnormal lipid levels in the blood, is a major risk factor for [[cardiovascular disease]]. Resmetirom's ability to lower LDL cholesterol and triglycerides makes it a candidate for managing dyslipidemia, particularly in patients with concurrent NASH.
-==Clinical Trials==
+==Safety and Tolerability==
-Clinical trials are crucial for assessing the efficacy and safety of Resmetirom in treating NASH. Phase 2 and Phase 3 trials have been conducted to evaluate its impact on liver health, lipid profiles, and other metabolic parameters in patients with NASH. These studies have shown promising results, indicating that Resmetirom can significantly reduce liver fat content and improve markers of liver fibrosis. However, as with any pharmaceutical agent, the outcomes of ongoing and future clinical trials will be vital in determining Resmetirom's role in NASH therapy.
+In clinical trials, resmetirom has been generally well-tolerated. Common adverse effects include mild gastrointestinal symptoms, such as [[nausea]] and [[diarrhea]]. The liver-selective action of resmetirom is intended to reduce the risk of systemic side effects typically associated with thyroid hormone therapies.
-==Potential Implications for Patient Care==
+==Future Directions==
-The development of Resmetirom represents a significant advancement in the treatment of NASH, a condition that currently lacks FDA-approved therapies and can progress to more severe liver diseases, including cirrhosis and hepatocellular carcinoma. By providing a targeted treatment option, Resmetirom has the potential to improve the quality of life for patients with NASH and reduce the burden of liver disease on healthcare systems.
+Ongoing research is focused on further elucidating the long-term efficacy and safety of resmetirom in larger and more diverse patient populations. Additionally, studies are exploring its potential benefits in other metabolic disorders beyond NASH and dyslipidemia.
 ==Conclusion==
-Resmetirom holds promise as a novel therapeutic agent for NASH, offering hope to patients and clinicians in managing this challenging condition. Its development underscores the importance of targeted therapies in modern medicine and the ongoing need for research and innovation in the treatment of liver diseases.
+Resmetirom represents a promising therapeutic agent in the management of NASH and dyslipidemia, with its liver-targeted mechanism offering a novel approach to these challenging conditions. Continued research and clinical trials will determine its place in future treatment paradigms.
-[[Category:Pharmaceuticals]]
+{{Drugs}}
-[[Category:Liver disease]]
+[[Category:Thyroid hormone receptor agonists]]
-{{Med-stub}}
+[[Category:Experimental drugs]]
+[[Category:Hepatology]]
+[[Category:Metabolic disorders]]